Conclusion. Patients de-escalated to oral therapy had fewer adverse events and similar incidences of treatment failure compared to patients maintained on parenteral vancomycin. Switching to oral therapy avoids some adverse events related to parenteral access. Our results in an uncontrolled, real-world setting are consistent with the OPTIVA trial. Though limited by sample size, our data indicate switching to oral therapy in patients with an orthopedic infection improves safety outcomes without compromising effectiveness compared to continued parenteral vancomycin therapy.

Disclosures. Russell J. Benefield, PharmD, Paratek Pharmaceuticals (Grant/Research Support)

233. Osteomyelitis of the jaw: A retrospective analysis of clinical, microbiologic characteristics and antimicrobial treatment at a tertiary care medical center. Thinh Nguyen, DMD; Sudheer Surpura, MD/ DMD; Leonor Echevarria, M.D.3; 1Banner Health, Phoenix, Arizona; 2Grand Canyon Oral and Facial Surgery, Henderson, Nevada; 3Albuquerque Veterans Affairs Medical Center, Albuquerque, New Mexico

Session: P-12. Bone and Joint

Background. Osteomyelitis of the jaw is a relatively rare entity in the post antibiotic era. The aim of this study is to describe clinical characteristics, microbiology, and antibiotic use (oral vs intravenous) for treatment. We review 5 years of experience at Banner University Medical Center–Phoenix (BUMC-P) of proven cases of OM jaw by clinical, pathological, radiological criteria.

Methods. Retrospective study of cases. From January 2011 to November 2015, 157 cases of osteomyelitis of the jaw, we excluded cases of radiation therapy or neoplasia to the head and neck region, a history of antiresorptive medication use. A total of 34 patients with diagnosis of osteomyelitis of the jaw were reviewed. All patients met criteria for diagnosis of osteomyelitis and underwent surgical debridement and received antibiotics that included parenteral, oral, and combined. We reviewed clinical, microbiology, antibiotic use. A successful outcome was defined as elimination of clinical symptoms, restoration of function and if available radiographic evidence of arrest and resolution of bony necrosis.

Results. This retrospective study involved 34 patients. Most common organisms were oropharyngeal flora 22 samples (65%); streptococcus anginosus group. 4 samples grew unusual gram negative bacteria. 10 (29%) samples grew fungal species. Antimicrobial regimen was divided in: intravenous (n=14) (41.2%), oral (n=7) (20.6%). Antimicrobial outcomes followed as follows: 13 (38.2%) The average antibiotic duration was 8.1 ± 4.7 weeks. We were able to follow up 30 patients, average follow up was 32.1-44.7 weeks. The overall success rate was (n=24) 80% with healing and. (n=6) (20%) treatment failure. There was more failure in the oral antibiotics group (n=3).

Conclusion. This study is limited by small numbers. Surgery and cultures should guide treatment of osteomyelitis of the jaw. The use of oral antimicrobial therapy was associated with a higher likelihood of treatment failure. Although rarely linked as a cause of osteomyelitis, the authors think that the cultivation of candida spp should prompt appropriate coverage. More study is required to understand the efficacy of oral anti-microbial therapy in treating osteomyelitis of the jaw.

Disclosures. All Authors: No reported disclosures

234. Dalbavancin versus Outpatient Parenteral AntiMicrobial Therapy with Vancomycin for Treatment of Bone and Joint Infections in a Veteran Population. Emily A. Gibbons, PharmD, AAHPHP1; Tara L. Hopkins, PharmD, BCIDP, BCPS2; Manuel R. Escobar, PharmD1; Linda Yang, Pharm.D., BCIDP, BCPS2; Elizabeth Walter, MD, FACP3; Jose Cadena-Zuluaga, MD2; 1South Texas Veterans Health Care System, San Antonio, Texas; 2South Texas Veterans Health Care System, UT Health San Antonio; 3Austin College of Pharmacy, Baltimore, Maryland; 4University of Texas health and science center San Antonio, Audie L. Murphy VA Medical Center, San Antonio, Texas

Session: P-12. Bone and Joint

Background. Dalbavancin is a long-acting lipoglycopeptide with broad gram-positive activity. A long half-life makes it an attractive treatment option for bone and joint infections (BJI). Previous studies have demonstrated efficacy of dalbavancin in the treatment of BJI. Based on these studies, our institution established a protocol for using dalbavancin as an alternative to IV antibiotics via PICC line.

Methods. Chart review was performed to compare outcomes of patients who were treated with dalbavancin versus vancomycin for BJI from 8/2017 – 7/2020. Patients that received two doses of dalbavancin for BJI were compared with patients who received OPAT with vancomycin during the same time period. Patients were excluded if they were bacteremic or received dalbavancin for another indication. Data was collected from the Veterans Health Administration’s Corporate Data Warehouse and retrospective chart review. No statistical analyses were performed due to the descriptive nature of this study.

Results. A total of 59 patients were included; 25 received dalbavancin and 34 received vancomycin. Relevant differences in baseline characteristics included a higher proportion of patients with osteomyelitis (88% vs 74%) and refractory infection (64% vs 44%) in the dalbavancin group. More patients in the dalbavancin group (38% vs 24%) were readmitted for the same infection within one year, required (29% vs 21%) additional surgical intervention, and had increased CRP on follow-up labs (32% vs 9%). Dalbavancin use likely expedited discharge in at least 5 cases where vancomycin levels were not therapeutic. No significant adverse effects due to dalbavancin were noted, aside from one patient with an increase in serum creatinine. In the vancomycin group, 8 patients changed antibiotics due to adverse effects or difficulty managing levels and 3 patients had ED visits for PICC line care.

Conclusion. Dalbavancin may be a safe PICC-sparring treatment for BJI, particularly in cases where compliance is of concern, or there are logistical or tolerability issues with vancomycin. Our findings do raise concern for worse outcomes with dalbavancin, but the small sample size, difference in baseline characteristics between groups and descriptive nature of the study preclude any conclusions from being drawn.

Disclosures. All Authors: No reported disclosures

235. Outcomes Associated with Extended Oral Antibiotic Prophylaxis After 2-Stage Exchange Surgery to Prevent Recurrent Prosthetic Joint Infection. Martin L. Schweizer, PharmD2; Poorani Sekar, MD3; Bruce Beck, MA2.

Discussion. This retrospective cohort study included patients with hip, knee, or shoulder PJI who underwent 2SE at 83 VA hospitals between the years 2003-2017. PJI was defined using administrative and microbiology data. Patients were followed for 5 years to assess treatment failure (TF) and ARs. TF was defined as recurrent PJI, debridement, or reoperation. ARs included Clostridioides difficile infections (CDI), or antibiotic associated diarrhea (AAD) during or 72 hours after antibiotics. Chi-square tests were used to compare outcomes. Cumulative incidence function curves were created to compare TF rates between those who did and did not receive extended antibiotic treatment, incorporating the competing risks of TF and death.

Results. Of the 433 patients, most (97%) received < 1 month of oral antibiotics and 3% received extended antibiotics. The 15 patients who received extended antibiotics had similar rates of TF and ARs compared with patients who received < 1 month of oral antibiotics (Table). However, there was a trend toward higher rates of CDI (6.7% vs. 3.8%) and AAD (13.3% vs. 9.6%) among those who received extended antibiotics. There was no difference in TF comparing extended antibiotics with < 1 month of anti-biotics, accounting for death (Figure).

Table: Treatment Failure and Adverse Reactions Among Those Who Did and Did Not Receive Extended Antibiotics

| Treatment Failure | 1-3 Months Oral Antibiotics (n=418) | 1-3 Months Oral Antibiotics (n=15) |
|-------------------|------------------------------------|----------------------------------|
| TF                | 14 (3.4%)                          | 3 (20.0%)                        |
| AAD               | 46 (11.0%)                         | 2 (13.3%)                        |

| Adverse Reactions |
|-------------------|
| C. difficile Infecion | 16 (3.9%) |
| Antibiotic Associated Diarrhea | 40 (9.6%) |
Conclusion. Few patients received extended oral antibiotics in the study period. There were no statistically significant differences in TF or ARs between the 2 groups. Yet, there was a trend toward higher rates of ARs among the extended antibiotic group. Future prospective studies should assess both the potential benefits and ARs associated with extended antibiotics among patients undergoing 2SE surgery.

Disclosures. Marin L. Schweizer, PhD, 3M (Grant/Research Support) Bruce Alexander, PharmD, Bruce Alexander Consulting (Independent Contractor) Daniel Suh, MS MPH, General Electric (Shareholder) Merck (Shareholder) Moderna (Shareholder) Smile Direct Club (Shareholder) Aaron J. Tande, MD, UpToDate.com (Other Financial or Material Support, Honoraria for medical writing) Andrew Pugely, MD, MBA, Globus Medical (Research Grant or Support) Medtronic (Consultant) United Healthcare (Consultant)

236. Insight of Polymicrobial Prosthetic Joint Infections at a Referral Hospital

Diana Fernández-Rodríguez, n/a; Maria de Lourdes García-Hernández, Chemist; Guillermo Cerón-González, Chemist; Claudia Adriana Colín-Castro, Chemist; Melissa Hernández-Durán, Chemist; Mercedes Isabel Cervantes-Hernández, Chemist; Luis Esaú López-Jácome, Chemist; Noé Becerra-Lobato, Biologist; Jaime Arturo Mondragón-Eguiluz, Infectious Diseases Specialist; Edgar Samuel Vanegas-Rodríguez, Infectious Diseases Specialist; Rafael Franco-Cendejas, Chief of Infectious Diseases Division; MD/PhD Plan de Estudios Combinados en Medicina (PECEM), Mexico City, Distrito Federal, Mexico; Instituto Nacional de Rehabilitación “Luis Guillermo Ibarra Ibarra”, Mexico City, Distrito Federal, Mexico

Session: P-12. Bone and Joint

Background. Approximately one-third of the prosthetic joint infections (PJIs) are polymicrobial. They are difficult to treat and there is an urgent need of clinical evidence that help to guide current protocols. We aimed to define the clinical characteristics and outcomes of patients with polymicrobial PJI.

Methods. We conducted a retrospective cohort study of patients with polymicrobial PJI treated at a referral hospital in Mexico City. Clinical data was retrieved and analyzed. Time to treatment failure, was evaluated for all cases.

Results. We identified 166 patients with a polymicrobial PJI from July 2011 to October 2020. The median follow-up period was 3.24 years (IQR, 1.45-6.42). Fistulae (77.7%) and pain (76.5%) were frequent. Patients required a median of 2 (IQR, 1-3) hospitalizations and 3 (IQR, 1-5) surgeries. Relapse, reinfection, and amputation occurred in 21.1% (35), 10.2% (17), and 7.2% (12) of the cases, respectively. At 1-year follow-up 38.47% (63) patients failed to control the infection. At 2 and 5-year follow-up this rate increased to 50% (83) and 68% (112), respectively. The main infecting microorganisms were Staphylococcus epidermidis (51.8%), Enterococcus faecalis (47.6%), and Staphylococcus aureus (34.9%). Anaerobes were identified in 38 (22.9%) cases. At 1 and 5-year follow-up, 39.31% (34) and 71.1% (61) of patients with S. epidermidis experienced treatment failure. On the other hand, those with S. aureus showed lower rates (log-rank p-value=0.03): 24.85% (14) and 50% (29), accordingly. Patients affected by anaerobes and E. faecalis exhibited similar trends, between them (log-rank p-value=0.73).

Table 1. Clinical findings of patients with polymicrobial PJI.

| Total | n=166 |
|-------|-------|
| Sex, female | 86 (52) |
| Age, median (IQR) | 63 (46-73) |
| Abnormal weight | 117 (70.5) |
| Overweight | 49 (29.5) |
| Obese | 68 (41.0) |
| ASA III | 125 (75.3) |

| Affected joint | 106 (63.9) |
| Hip | 52 (31.3) |
| Knee | 37 (22.3) |
| Arthroplasty indication | 89 (53.6) |
| Osteoarthritis | 2 (1-3) |
| Number of hospitalizations, median (IQR) | 3 (1-5) |
| Pain | 129 (77.7) |
| Fever | 127 (76.5) |
| CRP (mg/dL), average ± SD | 45.88 ± 53 |
| ESR (mm/hr), average ± SD | 32.18 ± 13.17 |
| Leukocyte (10^9/L), average ± SD | 8.41 ± 3.64 |
| Relapse | 35 (21.1) |
| Reinfecction | 17 (10.2) |
| Suppressive antimicrobial therapy | 11 (6.6) |
| Treatment failure | 98 (59.0) |
| Limb amputation | 12 (7.2) |
| Death | 3 (1.8) |

Out-patient treatment | 98 (59.0) |
Quinoline | 82 (49.4) |
Rifampin | 57 (34.3) |
SXT | 39 (23.5) |
Antibiotics | 5 (3.0) |
Antifungal | 6 (3.6) |
S. epidermidis | 86 (51.8) |
E. faecalis | 79 (47.6) |
S. aureus | 58 (34.9) |
Anaerobes | 38 (22.9) |

Frequency distributions of sociodemographic factors, comorbidities, clinical presentation, outcomes, out-patient treatment, and etiology in patients with polymicrobial PJI. Data is presented as absolute frequency followed by relative frequency enclosed in parenthesis, otherwise specified. Abbreviations: SXT, Trimethoprim/Sulfamethoxazole.